{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T17:24:13Z","timestamp":1775064253545,"version":"3.50.1"},"reference-count":53,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>Mental health is an important segment in preserving overall health and represents a significant public health issue. In modern times, mental health disorders have risen, often requiring complex pharmacotherapy and chronic monitoring. The aim of this research was to determine the prevalence and clinical significance of potential psychotropic drug interactions in outpatient settings and compare the differences in potential drug\u2013drug interaction (pDDIs) exposure with age. The psychotropic drugs included antipsychotics\u2014N05A, anxiolytics\u2014N05B, hypnotics and sedatives\u2014N05C, and antidepressants\u2014N06A. This retrospective study analyzed prescribed pharmacotherapy in 492 outpatients who were treated with at least one psychotropic drug. We determined 1.64 prescribed psychotropic drugs per patient and 2.2 pDDIs that involved psychotropic drugs. In total, 2285 pDDIs were recorded, of which almost half (47.6%) were pDDIs with psychotropic drugs. More prescribed psychotropic drugs were found in patients younger than 65 years, and equal exposure to pDDIs of psychotropic drugs (p = 0.5077) was found in both age groups. The most commonly identified psychotropics involved in pDDIs were benzodiazepines, promazine, and zolpidem. The results indicate that psychotropic drug interactions represent important drug-related problems for primary health care. The widespread use of psychotropic drugs and the determined clinical significance of their interactions require pharmacist interventions which can reduce the prevalence of pDDIs and increase patient safety.<\/jats:p>","DOI":"10.3390\/pharmacy12060174","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T04:21:36Z","timestamp":1732249296000},"page":"174","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Assessment of Potential Drug\u2013Drug Interactions of Psycholeptics and Antidepressants in Outpatient Settings"],"prefix":"10.3390","volume":"12","author":[{"given":"Iva","family":"Marovi\u0107","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, University Hospital Dubrava, 10 000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Marinovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University Hospital Dubrava, 10 000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vesna","family":"Ba\u010di\u0107 Vrca","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy and Biochemistry, University of Zagreb, 10 000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Samard\u017ei\u0107","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University Hospital Dubrava, 10 000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"key":"ref_1","unstructured":"(2024, October 11). Mental Disorders. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/mental-disorders."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S2215-0366(21)00292-3","article-title":"Psychotropic Medicine Consumption in 65 Countries and Regions, 2008\u20132019: A Longitudinal Study","volume":"8","author":"Brauer","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"ref_3","unstructured":"(2024, October 11). Annual Report on Drug Utilisation for 2023\u2014Croatian Document. Available online: https:\/\/halmed.hr\/Novosti-i-edukacije\/Publikacije-i-izvjesca\/Izvjesca-o-potrosnji-lijekova\/Izvjesce-o-potrosnji-lijekova-u-Republici-Hrvatskoj-u-2023\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jpsychires.2019.08.002","article-title":"Changes in the Global Burden of Depression from 1990 to 2017: Findings from the Global Burden of Disease Study","volume":"126","author":"Liu","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1001\/jamainternmed.2014.949","article-title":"Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: The EMPOWER cluster randomized trial","volume":"174","author":"Tannenbaum","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"20451253211011007","DOI":"10.1177\/20451253211011007","article-title":"Clinical Pharmacist Interventions in Elderly Patients with Mental Disorders in Primary Care Focused on Psychotropics: A Retrospective Pre-Post Observational Study","volume":"11","author":"Stuhec","year":"2021","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Stuhec, M., and Zorjan, K. (2022). Clinical Pharmacist Interventions in Ambulatory Psychogeriatric Patients with Excessive Polypharmacy. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-15657-x"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2045125320957120","DOI":"10.1177\/2045125320957120","article-title":"Rates and correlates of pharmacotherapy-related problems among psychiatric inpatients: A representative Danish study","volume":"10","author":"Kibsdal","year":"2020","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2165\/00002018-200528050-00001","article-title":"Potential determinants of drug-drug interaction associated dispensing in community pharmacies","volume":"28","author":"Becker","year":"2005","journal-title":"Drug Saf."},{"key":"ref_10","first-page":"601","article-title":"Pharmacokinetic drug-drug interaction and their implication in clinical management","volume":"18","author":"Palleria","year":"2013","journal-title":"J. Res. Med. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Magro, L., Arzenton, E., Leone, R., Stano, M.G., Vezzaro, M., Rudolph, A., Castagna, I., and Moretti, U. (2021). Identifying and Characterizing Serious Adverse Drug Reactions Associated with Drug-Drug Interactions in a Spontaneous Reporting Database. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.622862"},{"key":"ref_12","first-page":"13","article-title":"Psychotropic medications in older adults: A review","volume":"28","author":"Kralik","year":"2016","journal-title":"Psychiatr. Danub."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jamapsychiatry.2013.3074","article-title":"National Trends in the Mental Health Care of Children, Adolescents, and Adults by Office-Based Physicians","volume":"71","author":"Olfson","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Luo, Y., Kataoka, Y., Ostinelli, E.G., Cipriani, A., and Furukawa, T.A. (2020). National prescription patterns of antidepressants in the treatment of adults with major depression in the US between 1996 and 2015: A population representative survey based analysis. Front. Psychiatr., 11.","DOI":"10.3389\/fpsyt.2020.00035"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.sapharm.2015.09.004","article-title":"Identifying high risk medications causing potential drug-drug interactions in outpatients: A prescription database study based on an online surveillance system","volume":"12","author":"Toivo","year":"2016","journal-title":"Res. Social. Adm. Pharm."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"L\u00e9tinier, L., Cossin, S., Mansiaux, Y., Arnaud, M., Salvo, F., Bezin, J., Thiessard, F., and Pariente, A. (2019). Risk of Drug-Drug Interactions in Out-Hospital Drug Dispensings in France: Results From the DRUG-Drug Interaction Prevalence Study. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.00265"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/ajhp\/61.4.380","article-title":"Evaluation of Personal Digital Assistant Software for Drug Interactions","volume":"61","author":"Barrons","year":"2004","journal-title":"Am. J. Health-Syst. Pharm. AJHP Off. J. Am. Soc. Health-Syst. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF03256929","article-title":"Potential Drug-Drug Interactions Associated with Prolonged Stays in the Intensive Care Unit: A Retrospective Cohort Study","volume":"31","author":"Moura","year":"2011","journal-title":"Clin. Drug Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40801-018-0143-z","article-title":"Impact of Definitive Drug\u2013Drug Interaction Testing on Medication Management and Patient Care","volume":"5","author":"Arnold","year":"2018","journal-title":"Drugs\u2014Real World Outcomes"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/14740338.2018.1546841","article-title":"An update on the clinical consequences of polypharmacy in older adults: A narrative review","volume":"17","author":"Wastesson","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4103\/0973-1229.104497","article-title":"Polypharmacy in psychiatry: A review","volume":"11","author":"Kukreja","year":"2013","journal-title":"Mens. Sana Monogr."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Taylor, A.W., Price, K., Gill, T.K., Adams, R., Pilkington, R., Carrangis, N., Shi, Z., and Wilson, D. (2010). Multimorbidity\u2014Not just an older person\u2019s issue. Results from an Australian biomedical study. BMC Public Health, 10.","DOI":"10.1186\/1471-2458-10-718"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0140-6736(12)60240-2","article-title":"Epidemiology of multimorbidity and implications for health care, research, and medical education: A cross-sectional study","volume":"380","author":"Barnett","year":"2012","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"101860","DOI":"10.1016\/j.eclinm.2023.101860","article-title":"Global and regional prevalence of multimorbidity in the adult population in community settings: A systematic review and meta-analysis","volume":"57","author":"Chowdhury","year":"2023","journal-title":"EClinicalMedicine"},{"key":"ref_25","unstructured":"(2024, October 11). Elderly Population. Available online: https:\/\/www.oecd.org\/en\/data\/indicators\/elderly-population.html."},{"key":"ref_26","unstructured":"(2024, October 11). Population Structure and Ageing. Available online: https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php?title=Population_structure_and_ageing."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.eurpsy.2015.05.001","article-title":"Gender Differences in Psychotropic Use across Europe: Results from a Large Cross-Sectional, Population-Based Study","volume":"30","author":"Boyd","year":"2015","journal-title":"Eur. Psychiatry J. Assoc. Eur. Psychiatr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.31887\/DCNS.2017.19.2\/bbandelow","article-title":"Treatment of Anxiety Disorders","volume":"19","author":"Bandelow","year":"2017","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1600-0047.2004.00325.x","article-title":"12-Month Comorbidity Patterns and Associated Factors in Europe: Results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) Project","volume":"109","author":"Alonso","year":"2004","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","article-title":"Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"ref_31","first-page":"3","article-title":"Overview of Key Data from the European Study of the Epidemiology of Mental Disorders (ESEMeD)","volume":"68","author":"Alonso","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"ref_32","unstructured":"(2024, November 11). Mental Health Treatment Among Adults Aged 18\u201344: United States, 2019\u20132021, Available online: https:\/\/stacks.cdc.gov\/view\/cdc\/120293."},{"key":"ref_33","unstructured":"Roche Products Limited (2024, October 11). Valium 5 mg Tablets: Summary of Product Characteristics. Available online: https:\/\/www.hpra.ie\/img\/uploaded\/swedocuments\/LicenseSPC_PA0050-017-002_22072015110144.pdf."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1365-2125.2008.03185.x","article-title":"Inappropriate benzodiazepine use in older adults and the risk of fracture","volume":"66","author":"Schoofs","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_35","unstructured":"(2024, October 11). FDA Drug Safety Communication: FDA Warns About Serious Risks and Death When Combining Opioid Pain or Cough Medicines with Benzodiazepines; Requires Its Strongest Warning, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-about-serious-risks-and-death-when-combining-opioid-pain-or."},{"key":"ref_36","first-page":"192","article-title":"Clinical Toxicology: Part I. Diagnosis and Management of Common Drug Overdosage","volume":"4","author":"Worthley","year":"2002","journal-title":"Crit. Care Resusc. J. Australas. Acad. Crit. Care Med."},{"key":"ref_37","unstructured":"(2024, October 11). A Guide to Deprescribing Benzodiazepines. Available online: https:\/\/www.primaryhealthtas.com.au\/wp-content\/uploads\/2023\/03\/A-guide-to-deprescribing-benzodiazepines.pdf."},{"key":"ref_38","unstructured":"(2024, October 11). Benzodiazepines & Z-Drug (BZRA) Deprescribing Algorithm. Available online: https:\/\/deprescribing.org\/wp-content\/uploads\/2019\/03\/deprescribing_algorithms2019_BZRA_vf-locked.pdf."},{"key":"ref_39","first-page":"339","article-title":"Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline","volume":"64","author":"Pottie","year":"2018","journal-title":"Can. Fam. Physician."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/bcp.14947","article-title":"Community-based pharmacists\u2019 role in deprescribing: A systematic review","volume":"88","author":"Kummer","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1742-7843.2008.00276.x","article-title":"Tramadol-induced seizurogenic effect: A possible role of opioid-dependent gamma-aminobutyric acid inhibitory pathway","volume":"103","author":"Rehni","year":"2008","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMra041867","article-title":"The serotonin syndrome","volume":"352","author":"Boyer","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_43","first-page":"1439","article-title":"Serotonin syndrome: A brief review","volume":"168","author":"Birmes","year":"2003","journal-title":"CMAJ"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1212\/WNL.45.2.219","article-title":"Serotonin syndrome","volume":"45","author":"Bodner","year":"1995","journal-title":"Neurology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/08971900221121371","article-title":"Prevalence of QT-Prolonging Drug-Drug Interactions in Psychiatry: A Systematic Review and Meta Analysis","volume":"37","author":"Ramasubbu","year":"2024","journal-title":"J. Pharm. Pract."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/2042098612454283","article-title":"Drug-Induced QT Interval Prolongation: Mechanisms and Clinical Management","volume":"3","author":"Nachimuthu","year":"2012","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/1715163516641136","article-title":"Drug-Induced QT Interval Prolongation and Torsades de Pointes: Role of the Pharmacist in Risk Assessment, Prevention and Management","volume":"149","author":"Tisdale","year":"2016","journal-title":"Can. Pharm. J. CPJ Rev. Pharm. Can. RPC"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00228-017-2381-5","article-title":"Risk factors for QTc interval prolongation","volume":"74","author":"Heemskerk","year":"2018","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1017\/S2045796015000906","article-title":"Prevalence and correlates of QTc prolongation in Italian psychiatric care: Cross-sectional multicentre study","volume":"25","author":"Bighelli","year":"2016","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2146\/ajhp070279","article-title":"Association of antipsychotic and antidepressant drugs with Q-T interval prolongation","volume":"65","author":"Zemrak","year":"2008","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/postgradmedj-2020-138661","article-title":"Managing drug-induced QT prolongation in clinical practice","volume":"97","author":"Khatib","year":"2021","journal-title":"Postgrad. Med. J."},{"key":"ref_52","first-page":"249","article-title":"Dual-Channel Learning Framework for Drug-Drug Interaction Prediction via Relation-Aware Heterogeneous Graph Transformer","volume":"38","author":"Su","year":"2024","journal-title":"Proc. AAAI Conf. Artif. Intell."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Lin, X., Quan, Z., Wang, Z.J., Ma, T., and Zeng, X. (2021, January 7\u201315). KGNN: Knowledge Graph Neural Network for drug-drug interaction prediction. Proceedings of the Twenty-Ninth International Joint Conference on Artificial Intelligence (IJCAI-20), Yokohama, Japan.","DOI":"10.24963\/ijcai.2020\/380"}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/12\/6\/174\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:37:17Z","timestamp":1760114237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/12\/6\/174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":53,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["pharmacy12060174"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy12060174","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,22]]}}}